DelveInsight's In Situ Hybridization Market Insights report provides the current and forecast market analysis, individual ...

Vitro, a global developer, manufacturer and marketer of integral diagnostics solutions and data integration in Cancer Diagnostics, today announced that it has appointed Biocare Medical, a global ...

The demand for in situ hybridization is experiencing significant growth, mainly due to the rising rates of cancer and genetic disorders. This trend is further driven by the increasing incidence ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group In 467 consecutive patients with ALL (0-20 years), we compared RNA sequencing (RNAseq), fluorescence ...

NeoGenomics, Inc.’s NEO share price has dipped by 10.05%, which has investors questioning if this is right time to buy.

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces ...

in order to investigate the efficacy and tolerance of trastuzumab in combination with paclitaxel and carboplatin in patients with HER2-positive (fluorescence in situ hybridization [FISH] positive ...

After six years of suffering from infertility that doctors couldn’t explain, Michelle R. was ready to take more desperate ...

Fort Myers-headquartered NeoGenomics acquired New Jersey CLIA/CAP/NYS-certified laboratory Pathline LLC, expanding the ...